Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313477 | 0.92 | KAT2B (0.69) | LMNAKAT2BMAPTALDH1A1POLB | |
| SCHEMBL15060715 | 0.86 | KAT2B (0.61) | LMNAKAT2BMAPTALDH1A1PTGER4 | |
| SCHEMBL2552231 | 0.84 | LMNA (0.68) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL17845647 | 0.84 | LMNA (0.68) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL10576590 | 0.84 | LMNA (0.68) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL31121972 | 0.84 | LMNA (0.68) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL29719258 | 0.84 | LMNA (0.68) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL3636228 | 0.83 | KAT2B (0.69) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL15666204 | 0.82 | LMNA (0.79) | LMNAKAT2BMAPTALDH1A1HCAR3 | |
| SCHEMBL20266487 | 0.81 | ALDH1A1 (0.67) | LMNAMAPTALDH1A1HCAR3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | LMNA 2804/4885KAT2B 929/4885MAPT 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.